First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era.

ABSTRACT: Bruton tyrosine kinase inhibitors (BTKi) and the BCL2 inhibitor venetoclax, with or without the anti-CD20 monoclonal antibody Obinutuzumab, represent the preferred options for the first-line therapy of CLL because they are more effective and may improve quality of life. However, patient inclusion criteria are heterogeneous across trials designed for older patients, and the identification of CLL-specific parameters identifying unfit patients at risk of developing drug-specific adverse events is required to guide treatment choice. Due to inclusion/exclusion criteria in trials, higher discontinuation rates with BTKi were reported in real-world studies, and registry analyses provided useful information on factors predicting earlier discontinuation in a real-world setting. Though targeted agent

SUBMITTER: Urso A 

PROVIDER: S-EPMC10417156 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature